drugset
drugset / Trial / NCT05613946

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

NCT05613946 ↗

Phase 1 Completed 10 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this research is to determine the preferred microbubble agent (Lumason®, Optison®, and Definity®) for lymphatic channel visualization by ultrasound. This research will also evaluate the utility of preoperative high-frequency B-mode ultrasound with contrast-enhanced ultrasound for presurgical planning, and ultrasound shear wave elastography for assessing treatment response at 6-month follow up.

Timeline

Start
2022-12-15
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Definity Diagnostic / imaging agent 0.2 ml Other
Subject Definity Diagnostic / imaging agent 0.3 ml Other
Subject Lumason Diagnostic / imaging agent 0.2 ml Other
Subject Lumason Diagnostic / imaging agent 0.3 ml Other
Subject Optison Diagnostic / imaging agent 0.2 ml Other
Subject Optison Diagnostic / imaging agent 0.3 ml Other

Indications

lymphedema